4D Molecular Therapeutics, Inc.
- FDMT
- NASDAQ
- Biotechnology
- Gene Therapy
- AAV Vector Platform
- Ophthalmology
$12.29
Today +1.24%Quote Oct 19, 2026, 08:00 PM UTC
−19.25%over the last month
Max drawdown −23.6%From 1-month high −22.6%3 months +8.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
196
Market value
$863.6M
Approximate share count
Floor
$11.92
3.0% below price
Resistance
$12.53
2.0% above price
Price vs analyst targets
14 analysts
Lowest target
$20.00Highest target
$37.00
$20.00Highest target
$37.00
- Price $12.29
- Average target $29.67
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 141% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about FDMTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free